#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News What Shape and Size of Tablets Do Our Patients Prefer?

The size and shape of tablets can affect patients' compliance with treatment. The following article provides an overview of conclusions from two foreign studies focused on influencing the difficulty of swallowing and handling tablets depending on their shape and size.
Source: Cardiovascular Continuum 14. 3. 2022

News Interactive Case Study: Treatment of Neuropathic Pain in a Patient with Neurodegenerative Disease

We offer a brief case study of a polymorbid patient suffering from chronic pain, spasticity, and sleep disturbances, among other issues. Medical cannabis was advantageously introduced, helping to alleviate several symptoms. You can interactively explore how you would proceed in this case.
Source: Medical Cannabis 22. 4. 2024

News Neuraxpharm Introduces a New Form of Medical Cannabis

Since November 2022, a new medication containing an active full-spectrum cannabis extract –⁠ Naxiva Panaxol from Neuraxpharm –⁠ has been available in the Czech Republic. The cannabis extract is offered in collaboration with Panaxia Labs Israel. Both companies are key players in the European medical cannabis market. Their agreement ensures the distribution of these products not only in the Czech Republic but also in Switzerland and Germany.
Source: Medical Cannabis 16. 3. 2023

News According to which parameters can we best assess the quality of incontinence aids?

Properly chosen incontinence aid significantly influences the user's quality of life. When selecting incontinence aids, it is very important to consider their individual properties and parameters. While in European countries the absorbency of the aid is mainly assessed alongside the product's size and the user's gender, other parameters are evaluated elsewhere in the world. So what should we primarily focus on when choosing an aid?
Source: Incontinence 12. 5. 2022

News Reduction of Mortality in Patients After Abdominal Surgery in Critical Condition Thanks to Early Supplemental Parenteral Nutrition

Ensuring adequate nutrition is an important part of therapy for critically ill patients to achieve better clinical outcomes in terms of both survival and recovery speed. The preferred option is enteral nutrition (EN), which, however, cannot be provided for many reasons to patients after acute abdominal surgery. The results of studies assessing the efficacy of parenteral nutrition (PN) in this specific group of patients are inconsistent. The purpose of the study recently published in Clinical Nutrition was therefore to evaluate the effect of early supplementary parenteral nutrition in critically ill patients after acute abdominal surgery.
Source: Parenteral Nutrition 5. 5. 2022

News Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib

Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect in patients who have developed resistance during treatment with other ALK inhibitors. It has demonstrated efficacy in patients with ALK+ non-small cell lung cancer (NSCLC) who are refractory to crizotinib as well as in ALK+ NSCLC not previously treated with an ALK inhibitor. Post hoc analysis of the ALTA-1L trial, presented as a poster at this year's American Society of Clinical Oncology (ASCO) annual meeting, addresses whether the maximum reduction in target lesions of ALK+ NSCLC treated with brigatinib or crizotinib correlates with overall survival (OS) and progression-free survival (PFS).
Source: Non-Small Cell Lung Cancer 12. 9. 2022

News Does empagliflozin improve the overall health of patients with heart failure with reduced LVEF?

A recently published secondary analysis of the EMPEROR-Reduced study is based mainly on the results of the KCCQ-23 questionnaire, which assesses the patient's health status from their perspective. Its goal was to verify whether the benefit of empagliflozin added to the treatment of heart failure with reduced left ventricular ejection fraction (HFrEF) depends on the initial health status and how it subsequently affects the health status of these patients over 1 year.
Source: Heart Failure 21. 6. 2022

News Analgesic Effect of Metamizole in Cold-induced Pain

The cold test is used to experimentally induce acute pain –⁠ it can thus be used, for example, to test the efficacy of analgesics. The authors of a recently published German study evaluated the analgesic effect and tolerability of metamizole compared to opioid analgesics using this method. They were led by the fact that although the drug has proven clinical efficacy and safety, it has not yet been tested using this procedure, unlike opioids.
Source: Analgesia 5. 10. 2022

News Cardiovascular Benefit of SGLT2 Inhibitors Confirmed

The cardiovascular (CV) benefit of SGLT2 inhibitors in type 2 diabetics, demonstrated by empagliflozin in the EMPA-REG OUTCOME study, has also been confirmed by studies with canagliflozin (CANVAS), a new analysis of the CVD REAL study involving empagliflozin, canagliflozin, and dapagliflozin, as well as individual sub-studies of the EMPA-REG OUTCOME study. These findings, presented in June 2017 at the American Diabetes Association (ADA) congress, are summarized in a recently published article in the journal Critical Pathways in Cardiology.
Source: Diabetes 31. 1. 2020

News Technology as an Aid in Home Oral Care

Good oral hygiene is a prerequisite for good health, both in the mouth area and in terms of overall condition. To make it more effective and easier, it is now possible to use technologically advanced tools that allow users to achieve and maintain high hygiene standards in regular daily care.
Source: Dental Care 22. 2. 2023

News Current View on Obstacles in Proper Use of Antibiotics and the Role of Biomarkers in Infection Diagnosis

In the fight against antibiotic resistance, principles for the proper use of antibiotics (ATB) have been introduced globally. The following overview briefly describes the obstacles in leading rational antibiotic therapy and considers the use and benefits of biomarkers.
Source: Anti-Infectives 13. 4. 2023

News Infographic and Commentary from Practice: Reasons and Pathways for Patients to Biological Treatment of Asthma

For asthma patients with the most severe forms of the disease to access targeted biological treatment, they must undergo examination at one of the specialized centers for severe asthma. To facilitate this pathway, a recommended procedure has been issued, from which we present a pragmatic extract for practice in the form of a clear infographic.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 28. 4. 2023

News When Teriflunomide and Interferon Join Forces

Progressive multifocal leukoencephalopathy is a nightmare for all doctors prescribing disease-modifying therapies for multiple sclerosis. How Swiss colleagues dealt with this situation is illuminated by the following case study.
Source: Multiple Sclerosis 21. 12. 2021

Journal articles Telemedicine and inflammatory bowel disease –⁠ results of the IBD Assistant pilot project

Author of the article: Malíčková K., Pešinová V., Bortlík M., Ďuricová D., Machková N., Hrubá V., Lukáš M. Jr., Mitrová K., Vašátko M., Kostrejová M., Kolář M., Lukáš M. Source: Gastroenterologie a hepatologie | 1/2020 25. 2. 2020

News RETRO-TAS Study –⁠ Trifluridine/Tipiracil in Pretreated mCRC in Real-World Practice

How does trifluridine/tipiracil (FTD/TPI), which demonstrated efficacy in clinical trials in chemotherapy-refractory metastatic colorectal cancer (mCRC), fare in real-world practice? This was investigated by the authors of the Greek retrospective observational study RETRO-TAS.
Source: Treatment of Gastrointestinal Carcinomas 25. 5. 2023

News Persistent Symptom Control with s.c. Supplementation of C1 Inhibitor in Prophylactic Treatment of HAE

The open-label extension of the COMPACT study with subcutaneous C1 inhibitor in the prophylaxis of hereditary angioedema (HAE) has brought fresh results, shedding light on the treatment's impact on the frequency of attacks and reducing the need for rescue medication.
Source: Hereditary Angioedema 14. 11. 2022

News Successful Long-Term Subcutaneous Prophylaxis of Hereditary Angioedema –⁠ Case Study

Hereditary angioedema (HAE), arising from a deficiency of C1 inhibitor (C1-INH), clinically manifests as swelling of the subcutaneous tissue and mucous membranes. The standard prophylactic therapy consists of intravenous (i.v.) substitution of C1-INH. We present a case study of successful long-term subcutaneous (s.c.) prophylaxis in a patient who had to discontinue i.v. prophylaxis.
Source: Hereditary Angioedema 8. 12. 2022

Journal articles Importance of early diagnostics of inherited metabolic disorders in neonatal age

Author of the article: M. Magner, P. Ješina, P. Klement, D. Lorenčík, V. Vobruba, J. Zeman, T. Honzík Source: Česko-slovenská pediatrie | 1/2013 6. 2. 2013

News Collagen Turnover as a Biomarker of Hemophilia Treatment Efficacy

Over the past decades, hemophilia treatment has made significant progress—from factor therapy to prophylactic regimens and non-factor products, and even to gene therapy. Its development has greatly improved the quality of life for hemophiliacs and reduced the incidence of bleeding episodes. However, they cannot be completely eliminated, which is why further options for monitoring bleeding and joint status are still being explored. In addition to classical methods, biomarkers are attracting attention, but their practical use is still the subject of studies. A recently published work by a team of European and American experts, who assessed collagen turnover as a biomarker of treatment efficacy with rurioctocog alfa pegol, came with interesting results.
Source: Hemophilia 10. 6. 2024

News INFOGRAPHIC: Migraine Treatment Without Mistakes

A practical guide on how to proceed with the diagnosis of migraine, so that the treatment is effective and tailored to the patient.
Source: Migraine 22. 2. 2021

News Treatment with Osimertinib in Patients with NSCLC After Disease Progression on Previous Therapy –⁠ Case Study

We present a case study of a patient with non-small cell lung cancer (NSCLC) with a proven activating mutation of the epidermal growth factor receptor (EGFR) gene, who developed resistance to the first-generation EGFR tyrosine kinase inhibitor (TKI) gefitinib during treatment. After the secondary mutation EGFR T790M was confirmed, osimertinib, a third-generation EGFR TKI, was introduced, resulting in disease regression, which is ongoing. This case study illustrates the significance of the role of osimertinib in the treatment of patients with NSCLC with an activating EGFR mutation, whose disease progresses during treatment with first and second-generation EGFR TKIs due to the emergence of the secondary EGFR T790M mutation.
Source: Lung Cancer 16. 6. 2020

News Alpha-1 Antitrypsin Deficiency and Lung Disease in Patients with Primary Immunodeficiencies

Alpha-1 antitrypsin deficiency (AATD) plays a significant role in the pathogenesis of pulmonary emphysema, chronic obstructive pulmonary disease (COPD), and bronchiectasis. However, its deficiency may also play a role in other lung diseases.
Source: Deficiency of Alpha-1-Antitrypsin 1. 7. 2021

News Medium to Long-term Results of PFC Sigma Total Knee Arthroplasty

The PFC Sigma knee implant was introduced in 1997. It is the most commonly used system for total knee arthroplasty in England and Wales, accounting for 34.9% of primary implantations in 2006. Studies evaluating medium to long-term implantation outcomes have shown that it is an implant with a high survival rate, low re-implantation rate, and very good clinical results.
Source: Large Joints 23. 11. 2020

News Pathogenetic Mechanisms Underlying the Development and Progression of Interstitial Lung Diseases

Interstitial lung processes (ILP) represent an umbrella term for a wide range of nosological units that differ from each other in clinical course, prognosis, and pathogenesis. Most ILPs are characterized by inflammation or fibrosis of the interstitial space, leading to impaired gas exchange at the alveolocapillary membrane.
Source: Progressive Interstitial Pulmonary Processes 6. 12. 2022

Journal articles Involvement of the gastrointestinal tract in amyloidosis: when to think about it and how to diagnose

Author of the article: Ryšavá R. Source: Gastroenterologie a hepatologie | 2/2019 23. 4. 2019

1 21 22 23 24 25 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#